hall Senates, 11:10-12:00
Leveling up Biomedicine Ecosystem
Presentation & Workshop with the Ministry of Economics of the Republic of Latvia and the Investment and Development Agency of Latvia
"Excellence driven commercial research ecosystem.''
Member of Latvian diaspora D. Dimza-Jones (Deputy Head of Northern Powerhouse Life Sciences: Biotechnology & Pharmaceuticals Department for International Trade. Former Industry Facilitator at NIHR. Clinical Research Network Greater Manchester.):
will describe the UK’s clinical trial ecosystem and the importance of working with the industry to attract more commercially funded research studies. I will demonstrate examples of the existing infrastructure facilitated by the NIHR to enable a welcoming environment for clinical research and innovation to thrive. Lessons learned by working with the industry representatives will also be looked at. I will conclude by demonstrating examples of the importance of patient-led innovations and inclusive clinical research initiatives
Mg. sc. admin. Ieva Siliņa - Adviser to the Minister of Economics Ieva is also External Science and Education Policy Adviser to the President of Latvia and Former leader of Association of Latvian Young Scientists
Dr. Chem. Osvalds Pugovičs - Director of Organic Synthesis institute- TBC
Dr. Agrita Kiopa - Vice-Rector for Science (Rīga Stradiņš University)
Raimonds Lapiņš - Deputy State Secretary on Economic Development, Business Competitiveness, and Innovation of the Ministry of Economics of Latvia
Dr.Terje Peetso (TBC)- head of the eHealth and ageing policy sector in the Unit on eHealth, Wellbeing and Ageing in the European Commission's DG CONNECT. Member of the management board at the North Estonia Medical Centre
Ph.d. Lauma Muižniece - Director of Latvian Council of Science, Latvia CERN ILO, Assistant professor
About the Workshop
Within the framework of the state research program “Innovation Fund - Industry Research Programme”, created by the Ministry of Economics of the Republic of Latvia, support is available to research organizations for the financing of commercially oriented research projects in two RIS3 areas “Biomedicine, medical technologies, pharmaceuticals” and “Photonics and smart materials, technologies and engineering systems”. For such projects, especially in the field of biomedicine and pharmaceuticals, a long-term approach and flexibility to project financing are important, which the existing financing mechanisms cannot always provide. It is important to understand the pros and cons for funding research with commercialization potential.